EXPENDITURE STRATEGY - ASTRAZENECA

1) AstraZeneca plans to eliminate 3,000 jobs to reduce expenses to counter competition from copycat versions of Toprol XL.
2) About 4 cents a share was charged to cost of sales from the company's supply chain improvement program.
3) It forecast $500 million in synergies from the acquisition of MedImmune in the next five years.

Isn't there a way to prevent employees from being the first and largest shock casualties in business rationalization programs? Say a proactive, realistic, and continuously readjusting staffing policy with its ear to the ground?

[Click here for full story at: BLOOMBERG.COM]